Investing in AIM discussed at a ShareSoc Masterclass. June 2015

We’ve pulled this out of the archive, from 2015. It’s still as valid today, even if the story on some of the companies cited has changed.

Insight from David Stredder, ShareSoc Director/Mello; two ISA millionaires:
Lord John Lee & Leon Boros. And Henry Evans, Fund Manager, Killik & Co.

A beginner’s guide to the difference between AIM and the main market –
Henry Evans – 1:20

Why invest in AIM? – Henry Evans – 2:35

David Stredder’s top 16 holdings (all AIM) as at June 16, and his view
on AIM – 4:08

Leon Boros’s: views on AIM – 7:30

Selection process for AIM shares? Henry Evans – 8:40

Tax advantages of AIM – Leon Boros – 9:50

What wouldn’t you touch on AIM? David Stredder – 10:35

Selection of shares: Anpario, Concurrent Technologies, Lok’n Store –
Lord Lee – 11:46

AIM regulation – Leon Boros – 14:06

What frustrates you most about AIM? David Stredder – 16:32

Enforcement of AIM rules – Henry Evans – 17:45

Q&A NOMADS – 18:40

Q&A: Averaging down – 22:28

Q&A: Is there a difference between AIM and small caps on the main
market? And, is AIM more inefficiently priced? – 29:45


Videos from ShareSoc

International Biotechnology Trust IBT presentation at ShareSoc April 2018

International Biotechnology Trust (IBT) presentation at ShareSoc April 2018

IBT presentation at the ShareSoc growth company seminar in April 2018 by Lead Investment Manager Dr Carl Harald Janson. International Biotechnology Trust offers investors access to the fast growing biotechnology sector through an actively managed, diversified fund. Its award winning fund managers at SV Health Investors are scientifically and medically trained with over 60 years […]
K3 Business Technology (KBT) presentation at ShareSoc July 2018

K3 Business Technology (KBT) presentation at ShareSoc July 2018

K3 Business Technology (KBT) presentation at ShareSoc July 2018 By Adalsteinn Valdimarsson, CEO, and Rob Price, CFO. Adalsteinn Valdimarsson, CEO Business overview – 00:34 Product offering – 03:16 Reorganisation/Engagement models – 05:38 Channel partner network – 07:38 H1 results overview – 08:50 Rob Price, CFO H1 financial overview – 10:38 Adalsteinn Valdimarsson, CEO Summary – […]
MaxCyte (MXCT) presentation at ShareSoc July 2018

MaxCyte (MXCT) presentation at ShareSoc July 2018

Driving the next generation of cell-based medicines By Doug Doerfler – Founder, President & CEO Introduction – 00:23 Background and what MaxCyte does – 02:41 Business model – 04:11 CARMA platform, CAR therapy in oncology – 09:07 Cell therapy programmes – business model – 16:12 Revenue potential across multiple applications – 19:15 Expected news flow […]
ShareSoc Beaufort Securities Client campaign

ShareSoc Beaufort Securities Client campaign

Beaufort Securities Client campaign Introduced by Mark Northway Presented by Mark Bentley ShareSoc’s Mark Bentley discusses the Beaufort Scandal – an insight into the reasons behind the current debacle, the ignoble roles played by the FCA and PWC in this tragedy, ShareSoc’s initiatives to improve the outcome for Beaufort’s clients and the wider implications for […]

You might be interested in


Your email address will not be published. Required fields are marked *